High Expression Levels of Erythropoietin and Its Receptor Are Not Correlated with Shorter Survival in Human Glioblastoma

Overview

Journal Exp Ther Med

Specialty Pathology

Date 2012 Sep 15

PMID 22977501

Citations 1

Authors

J Brunotte

H C Bock

W Bruck

B Hemmerlein

H Strik

Affiliations

Soon will be listed here.

Abstract

Erythropoietin (EPO) is used to treat anemia in neoplastic disease. EPO also exerts neuroprotective effects on neuronal cells, making a prophylactic use against the neurocognitive effects of radiochemotherapy probable. However, EPO/EPO-receptor (EPOR) signalling has been also detected in glioblastoma cells. Data collected in vitro and in vivo show conflicting results on the effect of EPO on malignant gliomas. The association between EPO and EPOR expression and the prognosis of human glioblastomas was analyzed. Probes of human glioblastomas with complete documentation of clinical course and treatment were assessed by immunohistochemistry for the expression of EPO and EPOR (n=80). Using univariate and multivariate survival analysis, the association with age, gender, radiation, chemotherapy and extent of resection was determined. High levels of EPOR were correlated with a median survival advantage of 7 months (p<0.01). By univariate, but not multivariate, analysis, high levels of EPO and EPOR were associated with a significant prolongation of 7 months median survival when compared to low levels of both molecules. In patients treated with radiochemotherapy adjuvant to surgery, the median survival was 6.5 months longer in patients with high levels of EPOR (p<0.04). According to previous studies, longer patient survival is associated with EPOR expression. Therefore, EPO appears to be safe for the treatment of anemia in glioblastoma patients. However, a prophylactic use, i.e., for neuroprotection, is not recommended in light of the functional studies described in the literature.

Citing Articles

The effect of erythropoietin on normal and neoplastic cells.

Elliott S, Sinclair A Biologics. 2012; 6:163-89.

PMID: 22848149 PMC: 3402043. DOI: 10.2147/BTT.S32281.

References

Leyland-Jones B . Evidence for erythropoietin as a molecular targeting agent. Semin Oncol. 2002; 29(3 Suppl 11):145-54. DOI: 10.1053/sonc.2002.34067. View

Erbayraktar S, de Lanerolle N, de Lotbiniere A, Knisely J, Erbayraktar Z, Yilmaz O . Carbamylated erythropoietin reduces radiosurgically-induced brain injury. Mol Med. 2006; 12(4-6):74-80. PMC: 1578768. DOI: 10.2119/2006-00042.Erbayraktar. View

Sasaki R, Masuda S, Nagao M . Erythropoietin: multiple physiological functions and regulation of biosynthesis. Biosci Biotechnol Biochem. 2000; 64(9):1775-93. DOI: 10.1271/bbb.64.1775. View

Brizel D, Sibley G, Prosnitz L, Scher R, Dewhirst M . Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 1997; 38(2):285-9. DOI: 10.1016/s0360-3016(97)00101-6. View

Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P . Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 1996; 56(19):4509-15. View

Mulcahy L . The erythropoietin receptor. Semin Oncol. 2001; 28(2 Suppl 8):19-23. DOI: 10.1016/s0093-7754(01)90208-8. View

Mohyeldin A, Dalgard C, Lu H, McFate T, Tait A, Patel V . Survival and invasiveness of astrocytomas promoted by erythropoietin. J Neurosurg. 2007; 106(2):338-50. DOI: 10.3171/jns.2007.106.2.338. View

Nakamura Y, Komatsu N, Nakauchi H . A truncated erythropoietin receptor that fails to prevent programmed cell death of erythroid cells. Science. 1992; 257(5073):1138-41. DOI: 10.1126/science.257.5073.1138. View

Mittelbronn M, Capper D, Bunz B, Dietz K, Goeppert B, Ajaaj R . De novo erythropoietin receptor (EPO-R) expression in human neoplastic glial cells decreases with grade of malignancy but is favourably associated with patient survival. Neuropathol Appl Neurobiol. 2007; 33(3):299-307. DOI: 10.1111/j.1365-2990.2006.00820.x. View

10.

Bohlius J, Wilson J, Seidenfeld J, Piper M, Schwarzer G, Sandercock J . Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst. 2006; 98(10):708-14. DOI: 10.1093/jnci/djj189. View

11.

Khan F, Shukla A, Joshi S . Anaemia and cancer treatment: a conceptual change. Singapore Med J. 2008; 49(10):759-64. View

12.

Stupp R, Mason W, van den Bent M, Weller M, Fisher B, Taphoorn M . Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352(10):987-96. DOI: 10.1056/NEJMoa043330. View

13.

Davis F, McCarthy B, Freels S, Kupelian V, Bondy M . The conditional probability of survival of patients with primary malignant brain tumors: surveillance, epidemiology, and end results (SEER) data. Cancer. 1999; 85(2):485-91. View

14.

Molls M, Stadler P, Becker A, Feldmann H, Dunst J . Relevance of oxygen in radiation oncology. Mechanisms of action, correlation to low hemoglobin levels. Strahlenther Onkol. 1999; 174 Suppl 4:13-6. View

15.

Berdel W, Oberberg D, Reufi B, Thiel E . Studies on the role of recombinant human erythropoietin in the growth regulation of human nonhematopoietic tumor cells in vitro. Ann Hematol. 1991; 63(1):5-8. DOI: 10.1007/BF01714953. View

16.

Henke M, Laszig R, Rube C, Schafer U, Haase K, Schilcher B . Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet. 2003; 362(9392):1255-60. DOI: 10.1016/S0140-6736(03)14567-9. View

17.

Pinel S, Barberi-Heyob M, Cohen-Jonathan E, Merlin J, Delmas C, Plenat F . Erythropoietin-induced reduction of hypoxia before and during fractionated irradiation contributes to improvement of radioresponse in human glioma xenografts. Int J Radiat Oncol Biol Phys. 2004; 59(1):250-9. DOI: 10.1016/j.ijrobp.2003.12.022. View

18.

Leyland-Jones B, Semiglazov V, Pawlicki M, Pienkowski T, Tjulandin S, Manikhas G . Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol. 2005; 23(25):5960-72. DOI: 10.1200/JCO.2005.06.150. View

19.

Westphal G, Niederberger E, Blum C, Wollman Y, Knoch T, Rebel W . Erythropoietin and G-CSF receptors in human tumor cells: expression and aspects regarding functionality. Tumori. 2002; 88(2):150-9. DOI: 10.1177/030089160208800214. View

20.

Kelleher D, Mattheinsen U, Thews O, Vaupel P . Blood flow, oxygenation, and bioenergetic status of tumors after erythropoietin treatment in normal and anemic rats. Cancer Res. 1996; 56(20):4728-34. View